DocGo Inc. (DCGO) Earnings Call Transcript & Summary
March 16, 2026
Earnings Call Speaker Segments
Mike Cole
executivePrior to handing things off to management, I'd like to offer a few comments about forward-looking statements. Every statement on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as "may," "will," "plan," "potential," "could," "goal," "outlook," "design," "anticipate," "aim," "believe," "estimate," "expect," "intend," "guidance," "confidence," "target," "project," along with similar expressions, might be employed to flag those forward-looking statements. Such forward-looking statements don't guarantee future performance, and we can't assure you that our plans, intentions, outcomes, results, or expectations will be achieved or realized. By their nature, forward-looking statements carry substantial risks, uncertainties, and assumptions, a great many of which lie beyond our control and which might cause our actual results or outcomes, or when results or outcomes occur, to differ materially from what those forward-looking statements contain. Among these risks, uncertainties, and assumptions are, without limitation, the ones addressed in Risk Factors and other sections of DocGo Inc.'s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, our earnings release for this quarter, and additional reports and statements DocGo Inc. has filed with the SEC, all of which deserve your attention. What actually happens, what results are achieved, or when results or outcomes occur could differ materially from anything expressed or implied by these forward-looking statements. Furthermore, today's call mentions non-GAAP financial measures. Reconciliations between those non-GAAP financial measures and the most directly comparable GAAP financial measures appear in the earnings release and the Current Report on Form 8-K, which you can find posted on our website, docgo.com, and which is also filed with the SEC. What's shared on this call is accurate only as of the date discussed. Investors shouldn't presume that statements will stay relevant and operative at a later point. We assume no obligation to update anything discussed on this call to reflect events or circumstances arising after the date of this call, or to reflect new information or the occurrence of unanticipated events, except where the law requires it. With that, it's now my pleasure to hand the call over to Mr. Lee Bienstock, CEO of DocGo Inc. Lee, please go ahead.
Lee Bienstock
executiveThanks, Mike, and I appreciate everyone being here today. We reported a solid finish to the year, with $74.9 million in revenue for the fourth quarter and an adjusted EBITDA loss of $11.6 million. Revenue came in above what we had anticipated, which let us surpass the upper end of our revenue guidance, but our adjusted EBITDA loss ended up a bit larger than expected. The main reason was expenses tied to the final wind down of our migrant-related programs during the fourth quarter, and we don't anticipate those recurring in the future. On top of that, thanks to new customer expansions and better hiring rates, we're raising our 2026 revenue guidance to $290 million to $310 million, up from the prior guidance of $280 million to $300 million, and together with our cost efficiency initiatives, we now expect an adjusted EBITDA loss of $5 million to $10 million, versus the adjusted EBITDA loss of $15 million to $25 million we had projected before. Let me spend a few minutes walking through the specifics behind this improved outlook. To start, our virtual care offering, SteadyMD, is performing absolutely stellarly. In the fourth quarter, SteadyMD topped $8 million in revenue for the first time ever, surpassing the prior quarterly high by roughly $1 million. Because we only acquired SteadyMD in late October, we recorded $6.1 million in DocGo Inc.'s fourth quarter results. Meanwhile, SteadyMD's full-year over-year gross margin rose from approximately 30% to 37%, and we expect further gains in 2026. Integration work is still on track, and our goal is to consolidate provider networks so SteadyMD clinicians can deliver care to patients across DocGo Inc.'s mobile health offerings by the close of the second quarter. For full year 2025, SteadyMD surpassed 4 million patient interactions, made up of approximately 3 million lab orders and 1 million synchronous and asynchronous telehealth visits. That's up against roughly 2.5 million patients in 2024, which broke down into approximately 2 million lab orders and 500,000 synchronous and asynchronous telehealth visits. The fourth quarter was outstanding, and we expect this strong growth to keep going, fueled by the recent announcement of major customer expansions aimed at meeting demand for our customers' branded GLP-1 weight loss programs. Second, our hiring rates are improving considerably, which supports strong demand in our medical transportation segment and lets us outsource fewer rides while recognizing the associated revenue. Let me be clear; there's still considerable work ahead, but we've filled 206 EMT and paramedic roles out of the 546 that were open at the close of last quarter; in Q4, overtime rates in this segment landed in the teens, above our mid-single digits target; as hiring keeps improving, we're seeing that overtime rate gradually decline, and we expect it will offer some additional margin improvement potential as the year goes on. I couldn’t be more excited about the strides we’re taking to move the doctor’s office into the patient’s living room, and about how our key view metrics remain strong throughout the business. To illustrate, looking at our Q4 2025 figures against Q4 2024, medical transportation trips rose 11%, healthcare-in-the-home visits climbed 113%, mobile phlebotomy visits grew 16%, remote patients monitored were higher by 16%, and telehealth and lab orders jumped 50%. In addition, we kept growing our care gap closure programs alongside one of our top 10 national insurance payer customers, delivering annual preventative exams in Kentucky, with a launch anticipated later this month. With this payer, we now operate across California, New Mexico, and Kentucky; across our Care Gap Closure program overall, assigned lives rose 12% sequentially, going from 1.3 million in the prior quarter to more than 1.45 million at present. As our business with insurance payers expands, we keep honing how we deliver care in a way that boosts efficiency while preserving our exceptionally high customer satisfaction rate, which stood at an NPS score of 92 as of March 1. Toward that end, beginning in Q2 we intend to tap SteadyMD’s clinical network for the virtual components of our visits, and we are further broadening our use of AgenTeq AI and workflow automation across administrative and patient support functions. Although we’ll keep investing in this business, we anticipate that investment level dropping substantially as early markets mature and grow more self-sustaining, which lowers the cash outlay in 2026. Our aim is to expand this business — one we see as having considerable future strategic value — efficiently, in a way that curbs investment while supporting our objective of reaching profitability in 2026. Another highlight of the fourth quarter was our remote patient monitoring business, which produced record revenue of $4.0 million and $830,000 in adjusted EBITDA for the period. That result came from a 16% rise in patients monitored versus the same period in 2024, along with robust growth in our virtual care management offering; we’re achieving major margin improvements here as greater economies of scale kick in, and we anticipate further profitability gains through the rest of 2026. We also introduced our efficiency innovation portfolio in Q4. It’s a set of more than a dozen projects meant to boost and generate additional operating leverage in our P&L; they touch our medical transportation, mobile health, and corporate segments and should yield roughly $5 million to $6 million in savings during 2026 and roughly $20 million to $24 million in savings during 2027, once we realize the full annual benefit from these projects. At the heart of this effort is our technology use, which has long been a priority and a crucial differentiator for DocGo Inc. AgenTeq patient outreach is now part of our proprietary Dara ordering and routing platform, and we've brought automation into pre-billing to boost efficiency. Over the next few months, we intend to grow these programs and activate additional ones. I'm eager to talk more about that work on upcoming calls. As we announced in today's earnings release, DocGo Inc. has begun a process to examine a variety of strategic alternatives aimed at maximizing shareholder value. We can't guarantee that this effort will produce favorable outcomes, or that any deal will be found or pursued. Last, people frequently ask me when DocGo Inc. will turn profitable, and my answer is always that it comes down to three essential pieces: top-line revenue, gross margin, and SG&A. On revenue, demand for our services remains robust, and our volume metrics keep showing top-line growth. Our gross margin is getting better thanks to the strides we've made in hiring and in cutting overtime expenses. And we anticipate SG&A will improve as our efficiency innovation portfolio projects mature and deliver genuine results. I'll now pass things to Norm for the financial review. Norm, go ahead.
Norman Rosenberg
executiveThanks, Lee, and good afternoon to everyone. In Q4 2025, our total revenue came in at $74.9 million, which compares with $120.8 million during Q4 2024. That drop in revenue year over year stemmed completely from winding down projects tied to migrants. If we take out migrant-related revenues from each period, Q4 showed an 11% revenue gain year over year; looking at the whole year, total revenue reached $322.2 million in 2025 versus $616.6 million in 2024. Revenue from medical transportation services rose to $50.2 million in Q4 2025, up from the $49.1 million in transport revenues we posted in Q4 2024. Higher revenues came from gains across both large and small U.S. markets, with some of the strongest growth occurring in markets such as New York, Texas, and Tennessee. Mobile health revenue in Q4 2025 totaled $24.8 million, a decrease from $71.8 million in last year's fourth quarter, as a result of winding down migrant revenues. This year's figure included roughly $7.4 million in revenues related to migrants. Non-migrant mobile health revenues grew 47%, fueled by more care gap closures, remote patient monitoring, and mobile phlebotomy, along with two months of revenues from SteadyMD, which we acquired on October 20. Adjusted EBITDA for Q4 2025 showed a loss of $11.3 million, versus adjusted EBITDA of $1.1 million in Q4 2024. Across the full year, adjusted EBITDA loss came to $28.6 million in 2025, compared with adjusted EBITDA of $60 million in 2024. Adjusted gross margin, which strips out depreciation and amortization and is the margin measure we monitor most closely, stood at 32.5% in Q4 2025 versus 33.5% in Q4 2024. Throughout 2025, adjusted gross margins in the medical transportation segment reached 32.8%, compared with 30.1% in 2024, marking the highest gross margins for that segment since 2024. Even with those gains, medical transportation gross margins remain held back by effective hourly wages for field labor that came in above plan. As we noted on our previous call, our transportation business has been operating at the highest utilization rates on record, which pushes overtime rates up. Overtime made up roughly 13% of hourly wages in Q4 and has ranged from 11% — 13% over the past several quarters. That said, we made solid progress adding field headcount during Q4 2025, and we would anticipate the overtime rate declining in 2026, moving closer to the sub-10% overtime rates seen in 2024. That ought to give transportation gross margins a boost in 2026. Mobile health segment adjusted gross margin was 31.8%, versus 35.9% in 2024. Once we finished winding down migrant-related programs, we saw substantially lower gross margins in that area, which came in below 20% for the quarter; we anticipate mobile health segment gross margins improving in 2026 without those wind down costs and with larger relative contributions from higher-margin service lines including remote patient monitoring, mobile phlebotomy, and virtual care. This quarter's GAAP results were significantly affected by a number of nonrecurring, noncash items, and I'd like to walk through them. In the operating expense line, we took noncash charges stemming from write-downs of intangible assets and goodwill. Those write-downs reflect the ongoing disparity between the carrying value of our assets and our market cap. The process started back in the third quarter, when we wrote down goodwill and intangible assets tied to our clinical staffing business. Even following those write-downs, as we entered Q4, a meaningful amount of goodwill and intangible assets remained on our balance sheet, largely because of acquisitions we've completed over the past four years. During the fourth quarter, our market capitalization stayed well below our net asset value, which required us to evaluate adjusting the valuation of all our intangible assets and goodwill in an effort to narrow that gap, in accordance with ASC 350 and ASC 360. As of year end, we have now written down all the intangible assets and goodwill to zero. That produced a total goodwill impairment of $49.5 million, plus an impairment of intangible assets of an additional $22.6 million in the fourth quarter. Similarly, in the other expense line, we impaired the entire carrying value of an equity investment in a health care company that we made in previous years, which had an impact of $5 million in other expense. It's important to note that these write-downs are all accounting-driven and noncash in nature. They in no way reflect a change in the company's outlook regarding the future prospects or profitability of any of these underlying business lines. At year end, our total cash and cash equivalents, including restricted cash and investments, was $68.3 million, down from $95.2 million as of September 30, 2025. The biggest driver of the cash decline was the acquisition of SteadyMD in October. We paid $12.5 million in cash for SteadyMD and incurred additional transaction-related costs of approximately $1.5 million. Our cash balance at year end was lower than we had expected due to the delay in collecting migrant-related accounts receivable owed by New York City's Department of Housing Preservation and Development, which we had expected to see during the fourth quarter, coupled with an ongoing operating loss; with further operating losses expected during 2026, and several growth-related initiatives requiring working capital, we would expect further declines in cash in the near term, creating potential working capital pressure during 2026. To mitigate this, we are highly focused on reducing cash utilization and operating costs, particularly at the corporate level; we are also working with our current credit line provider to remedy issues related to certain financial covenants, which may increase borrowing costs while providing us with greater flexibility. Now looking ahead to 2026 — Lee touched on this earlier, and it's also in the press release — we've raised and revised our guidance for 2026, drawing on the first two-plus months of the year and the favorable volume momentum we're seeing across the majority of our business lines. Our full-year revenue outlook now sits at $290 million to $310 million, which is an increase from the $280 million to $300 million range we gave back in November. No revenues tied to migrant-related projects are included in this, and it works out to 15% to 23% growth against 2025 base revenues. On a full-year adjusted EBITDA basis, we expect a loss of $5 million to $10 million, versus the loss of $15 million to $25 million we previously guided to. Beyond the improved revenue outlook, we have a number of cost-cutting initiatives in motion that we're tackling through the efficiency innovation portfolio work Lee described earlier, and we think these can speed up our path to profitability; our expectation remains that we will reach profitability on an adjusted EBITDA basis in the back half of this year. With that, I'd like to hand the call back to the operator for Q&A. Operator, please proceed.
Pito Chickering
analystHi there, good afternoon, and I appreciate you taking my question. So, to kick things off, you mentioned running a formal process regarding a strategic alternative. Could you provide any details about, well, what that process actually involves, and any insight into how it's been going up to now?
Lee Bienstock
executiveHello, Pito. Of course. I appreciate the question. So, to pursue the aim of maximizing shareholder value, we've brought on an investment bank to conduct a formal process. Since we're currently in the middle of that process, we aren't able to share anything further right now. However, naturally, should matters move forward, we'll provide additional information when that happens.
Pito Chickering
analystAll right, that's reasonable. I suspected that was the case, yet I still needed to pose the question. Could you break down the enhancement in your 2026 outlook across revenues and EBITDA between gains from SteadyMD versus betterment in mobile health, transportation, or SG&A? Any detail at all would help, since you lifted revenues by $10 million and adjusted EBITDA by $10 million to $15 million.
Lee Bienstock
executiveOf course. I appreciate you asking that, Pito. What we're experiencing is higher volumes, especially within our medical transportation segment. We've additionally achieved advancement on EMS staffing. Those represent the two main elements behind the roughly $10 million higher revenue outlook; we're observing extra upside in SteadyMD, and those, I'd say, stand as the leading forces behind our raised guidance. Volumes at SteadyMD are up considerably, along with our capacity to meet the volumes we've encountered in the medical transportation segment through more hiring that has gone well for us. There remains a bit more headroom for us on the staffing front. That will stay a focus for us on the EMS side; yet that has genuinely been what propelled the revenue guide upward; regarding EBITDA, it truly comes down to, first, the revenue lift delivering additional gross profit dollars. We're additionally watching gross margin get better thanks to lower overtime that Norm highlighted. Thus we anticipate gross margin getting better as we begin this year and as we move forward, since we've managed to staff more efficiently and push that overtime rate lower; and then, once more, we're likewise quite concentrated on cutting SG&A by another 10% to 15% relative to recent levels via several of those efficiency innovation portfolio items that we've already launched. These are places where we're striving to automate a great many functions in billing and dispatch, where we can rely on potentially fewer staff members while harnessing automation to boost our efficiency. And we've already started that. I noted pre-billing as an area where we've already implemented that automation process improvement, and further areas will follow as we move through this year, using technology to grow more and more efficient and remove cost from the business. That's what's genuinely fueling the improved EBITDA outlook. Norm, anything you'd like to add?
Norman Rosenberg
executiveSure. What I'd say is this: looking at gross margin, the rate we exited the fourth quarter at came in at roughly 32.5% to 33% on a blended adjusted basis. But honestly, a few factors were dragging us down during Q4, and those have already gotten better in the first two, two and a half months of this year. First, on the transport side. Like Lee said, there's the overtime rate, and I can't stress enough how much a higher overtime rate hurts your overall gross margins. It pushes up your effective hourly rate. In the fourth quarter, the effective hourly rate for field labor was likely the highest we've ever had. Since then it's come down, with the overtime rate dropping from about 13% to closer to the 10% area we saw in 2024. So that's one factor. The second piece is mobile health gross margins — as it was winding down, the migrant revenue came in at a far, far lower gross margin level than before. Historically it had run in the 35% to 38% gross margin range, then in Q3 of last year it was maybe in the higher mid-twenties, and then under 20%; part of it is a stranded cost issue, but mostly it's just about keeping people on staff through the end of the year. A number of those projects wrapped up midway through December, and you're stuck with some cost. All of those costs are gone now. None of that will be in Q1, and neither will those revenues. So when we consider the exit rate and then consider where we'd set gross margin in our original guidance, particularly for the first half of the year, we believe we're running somewhat above that level.
Pito Chickering
analystAll right. Great. So, for my final question: you mentioned something like pressure on free cash flow in 2026, and possibly covenants. Could you put a number on how much free cash flow will be generated, or whether it will fall, during 2026? And any detail on how the year begins versus how it ends? And to be completely clear, is the rest of the migrant business's collections included in that, or not?
Norman Rosenberg
executiveAll right. There's a fair amount to unpack there, so let's take it in sequence. First, as we mentioned in our prepared remarks, our year-end cash balance came in below what we had projected. The reason is straightforward: roughly $20 million sits in those migrant receivables. The final portion — we've now collected 97% of everything to date — did not arrive in the fourth quarter. It still hasn't arrived in the first quarter. I think a sizable part of it is very close. By that I mean I still expect some of it to land in the first quarter, even with only a couple of weeks remaining, so it's quite near. The remainder will arrive in the second quarter, possibly the third quarter. But we anticipate collecting every bit of it, so looking ahead a few months, I wouldn't anticipate any net variance. That said, it's $20 million of receivables, or $20 million of cash, that I had thought, when we last spoke in November of last year, would be through the door and sitting in the bank by year-end, so that's one item. But to address your other question plainly, it doesn't shift — our view on the eventual collectability of that money remains the same. I'm simply looking at a cash balance that's somewhat below where it was previously. We do have working capital needs. As Lee said, we're adding a great many new people on the EMT side, so when you add an EMT, you begin paying them, you get them working in the field on the truck, they handle more volume, and typically those get paid within, you know, 80 to 90 days. So you've got your usual growth working capital needs there too. That's really what we're discussing. Regarding the line of credit, we have your standard covenant, or adjusted EBITDA covenant, and it's no secret that we've been operating at an EBITDA-negative level for a good few quarters. This is something we have to sort out together with them. Right now we're working alongside our credit line provider regarding the way they read that situation, and those sorts of adjustments, so that we can be sure the line of credit stays open for us. Since repaying it in August, we haven't taken anything from it. Still, it would be good to know it's available. Definitely good to know it's available. That's a major piece of this. When it comes to — I'd rather not, and I believe I've learned my lesson — I'd rather not peer into the crystal ball and discuss precisely what amount of cash will sit there on which date. Instead, just to give a sense of the direction, as we said, I think over the coming couple of quarters, when we anticipate negative EBITDA, at minimum in Q1 and Q2, and on into Q3, that will likely leave us with a somewhat reduced cash balance. Yet again, it hinges on when the remaining migrant receivables get paid. Once those arrive, they'll offset the loss. And in strict terms, that might hold us around a fairly flat level. So everything truly hinges on when that happens and when we make certain payments. But later, as we move toward the latter portion of the year, and we're seeing fairly modest EBITDA losses or perhaps even positive EBITDA figures by the back end of the year, at that point we ought to witness that particular cash balance leveling off.
Pito Chickering
analystExcellent. Thank you very much.
Ryan MacDonald
analystHello. I appreciate you fielding my questions. So, Lee, perhaps starting with the payer segment. Clearly, there's been strong traction when it comes to covered lives that keeps expanding, plus the move into Kentucky. And I believe earlier this year, during your conference, you mentioned something like a pipeline of two to four additional payers that might be brought on board during the first half of this year. Any word on how that pipeline is shaping up and whether it's included in even the raised top-line guidance, if at all, that you provided today?
Lee Bienstock
executiveOf course, Ryan. I appreciate that question. Wonderful to hear from you; so the guidance we possess, the guidance we gave today, aligns with what we offered on our prior call. We keep witnessing traction in this segment. Visit volume has risen considerably. As we noted, the count of lives and patients being directed to us by the payers has grown. And we keep striking a balance between scaling that segment and the investment we're putting into it. And that's the crucial element here. I believe the reason I was eager to announce the move into a new state by a payer we already partner with in two additional states is that it's a strong signal for us that the value we deliver to our partners is present. They're turning to us to broaden and deliver that value to more patients in other states; and that's a solid sign to us that, naturally, patients and the partners we collaborate with deeply appreciate the services we offer. And so that leaves us very, very thrilled; and, naturally, we witness it daily when we head out to visit patients and observe the difference we're creating. So the traction we're experiencing; we're truly concentrated on ensuring we grow efficiently, that we keep scaling while balancing the investment pace we're putting into this segment so that we might reach really critical mass in the markets we operate in and be extremely selective regarding whatever markets we move into, mainly with existing customers of ours. So that's the priority. I believe you'll see us visit in the patients' homes roughly 200,000 patients this year throughout our mobile lab and care-in-the-home business. Care gap, transition management, primary care is another major priority of ours where we're witnessing solid advancement. We always aimed when we got into this segment to not just close care gaps but deliver longitudinal preventative care. That's when you can genuinely affect the cost of care and enhance health outcomes, so we're witnessing strong advancement there too. So that's what the guidance comprises. Naturally, should we enter into further agreements, we'll make those public and modify our plans as needed over the course of the year.
Ryan MacDonald
analystGreat, thank you for that. Norm, it's clear that gross margin this year involves quite a few shifting elements — certain migrant revenues are dropping away, overtime rates are being reduced, and SteadyMD is being integrated to the point that, during the second quarter, you can begin handling a greater share of the mobile health visits via that platform. Could you provide some indication of what the forecast implies about where you see gross margins at each of the segment levels as well as at the total level when you consider the 2026 guide?
Lee Bienstock
executiveThanks.
Norman Rosenberg
executiveYes, at the risk of repeating what everyone else has already said, we do anticipate gross margin improvements happening quarter by quarter throughout this year. That's the first point I want to make. When you look at the whole year, we'd anticipate the blended gross margin landing at approximately 33%, so that represents a modest increase; over on the transport side, our adjusted gross margin last quarter stood at, I believe, 32.8%. I'll always be straightforward about this: gross margins can only go so high. Once we reach a situation where transport side gross margins hit 34.5% or 35%, we'd likely see that pull back somewhat. So on the transport side, I'd say that figure will hopefully be a bit above, slightly north of, 33% across the full year. And I can identify specific markets where we definitely anticipate a turnaround, plus there are 1 or 2 markets currently dragging us down where we've already observed some Q1 improvement. That covers the transport side. When it comes to mobile health, much of it depends on mix. We have the health plan provider care-in-the-home business, which carries a comparatively lower margin than what we see elsewhere; however the mobile phlebotomy business delivers a high margin. SteadyMD delivers a pretty high margin, though we've discussed how they've needed to scale up quickly, so you could even observe a stretch where SteadyMD margins dip somewhat alongside growth that exceeds plan. Then you've got your remote patient monitoring business, which keeps plugging along, rising both year-over-year and sequentially, and its margin is holding steady, above 50%. So we'd want to see mobile health margins return to, shall we say, a 35% blended level across the year, and that would essentially deliver that 33% for the full year.
Ryan MacDonald
analystGreat, thanks for that detail. I'll get back in line for another question.
David Larsen
analystHello. Could you break down the various revenue pieces for the 2026 guide? Previously, you've given that out by division — transport, municipalities, health systems, payers — plus RPM and virtual primary care. Getting any of those specifics by division would really help. Thanks.
Lee Bienstock
executiveOf course, Dave. Thanks for asking. So if we look at the midpoint of our revised guidance — roughly $300 million at the midpoint — what we now anticipate is that transport will land at approximately $215 million. We believe there's potential for more upside there should we keep advancing on the staffing front. And regarding the mobile health segment, it remains at that projected $85 million to $88 million of revenue. The mobile health portion, as you may recall, has no population health municipal revenue in it, does not include any migrant revenue, naturally, for 2026, and beyond that, we keep emphasizing that should we generate municipal or population health revenue, that will be reported as its own separate line item. So the mobile health side truly is made up of our SteadyMD acquisition, which is the virtual care piece; the care-in-the-home portfolio I mentioned; the mobile labs; the care gap; the primary care; and the patient monitoring, together with some of the staffed clinics we operate; those are genuinely the component parts. I'd note that we mentioned on earlier calls that SteadyMD falls within the $25 million to $30 million range. As Norm noted, we see upside to that plan, because of the progress we're achieving now that we've had more time with that business, since acquiring it in October. And we keep integrating and embedding them into the company and all the opportunities the company is encountering. So I'd say that's the mix. You've got that SteadyMD acquisition really reaching full bloom as we integrate it, and that mobile health group of businesses sits at $85 million to $88 million of revenue, none of which is migrant or municipal or population health in nature.
David Larsen
analystThat's quite useful, thanks. So could you discuss the cross-selling initiative? From what I can picture on the health plans side, closing care gaps delivers huge value. How often could you layer in remote patient monitoring, then have a primary care physician assigned, or is there your mobile lab offering? Could you speak to how much growth potential exists in cross-sell and upsell? Thanks.
Lee Bienstock
executiveYes. Excellent question. I'm delighted you raised it, since I believe this is frequently a genuinely untapped chance for us. I'd say we've captured part of it, and shortly I can share a few instances. Still, I believe a very large opportunity remains for the company — we've advanced somewhat on it, yet obviously there's additional opportunity we can capture as we truly sharpen our services portfolio. I'd say 2025 was a year in which we built a strong services portfolio across mobile health and medical transportation. Our value is quite evident. Patients are enthusiastic about it. And now we can begin considering how to cross-sell and deliver those offerings to patients more widely, especially since our two primary customer segments happen to be precisely the two segments you'd want in health care. We engage directly with big health systems and hospitals, plus the payers. So we're eager to sit at the middle of that. Within the system we contract and partner with in that space, the payers and hospitals are genuinely where the overwhelming share of touch points and cost originate; so let me offer a few instances. One area generating real excitement for us is our capacity to take a care gap patient and convert them into a preventative, primary, longitudinal care patient. We head out and perhaps close the care gap for a diabetes patient or perform some kind of screening. We discover that a lot of those patients lack a primary care provider or don't know who their primary care provider is; more than 70% of the time they'd choose us to serve as that primary care provider. So we're beginning to add that element of our offerings as we move into care gap and then primary care. Another item I'll mention too — you brought up the mobile labs — we're collaborating with several of the hottest consumer healthcare companies in the space, the wearable space, where they now provide lab orders, and they're embedding your lab results into their consumer apps for their wearables; and at present, they're sending patients to patient service centers, yet we hold partnerships with many of the labs. Maybe one possibility involves visiting those patients where they live, offered as an add-on and a handier choice compared with bringing them over to the patient service center — meaning we'd go into the residence and deliver mobile labs, to give one illustration. And our thinking hasn't changed that the chance sitting right there when we're at the bedside during discharge represents a really pivotal point in a patient's journey. At the moment the hospital is sending that patient home and our EMS crews are on hand moving those patients, with us at the bedside as discharge happens, we still believe that's a vital juncture within the healthcare journey. So what are we able to do in order to connect that discharge from the hospital over to the home? Our view is that we've got a significant part to play in this as we keep expanding the capabilities and keep collaborating with our fantastic partners. So those represent a few of the spaces we feel enthusiasm about, and that explains why my response here is so lengthy and thorough regarding it, since I believe it's one more territory of opportunity sitting before the company as we move ahead from here.
David Larsen
analystThank you so much. I'll get back in line again.
Sarah James
analystThanks. I value the remarks you've provided up to this point regarding certain dynamics in 2026, including migrant costs wrapping up during 2025 and the gains you've already observed in EMS labor so far this year; however, I'd like to know whether you could combine all of that with your SG&A efficiency plans and offer us a sense of how EBITDA should be expected to progress across the year. So, I suppose, given what you're doing regarding SG&A, does it represent a steady, even improvement over the year? Is this year going to be heavily weighted toward the back half, or what framework should we use?
Lee Bienstock
executiveYes. Thank you, Sarah, for asking. As Norm said, I believe we expect the bulk of the adjusted EBITDA loss to fall within the first half of the year, and once we get past that turning point into the second half, we move into profitability. The major elements, I'd say, involve lowering corporate expenses — on the headcount front and also with certain vendors we engage on the corporate side. A great deal of that effort has already been started, so that plays a role. Then, regarding efficiency, what I've really tasked the team with is figuring out how to operate more efficiently — leveraging technology, automating, and standardizing company processes in ways the patient and the customer never notice; they have no idea we're operating more efficiently. The service standards they've grown to love stay just as high as before. The patient experience that patients truly adore — I brought up the Net Promoter Score of 92 — remains as wonderful an experience as possible in a patient's home when they need healthcare, sustaining that elevated standard while simultaneously cutting cost. The method for achieving that involves technology and automation. So I gave the example of pre-billing; previously, our dispatchers and team members handled the pre-billing portion to confirm, naturally, that the patient had insurance coverage, that we could collect, for instance, on a medical transportation trip. Today we're striving to automate it, and we believe we've created something capable of automating that workflow, which then, naturally, frees our staff for other tasks or possibly lets us stay equally efficient and productive while employing fewer individuals. That genuinely serves as a key driver. So we're actively examining places where human labor is currently used but could be automated or standardized. Those are precisely the places where we're deploying technology to develop solutions. One more strong illustration I can point to is that back when we initially began working with the patient lists the payers supply to us for care gap services, every one of those patients was getting a phone call from us — I was among the people making them. I personally handled a number of those calls; engaging with patients is actually pretty rewarding, I should say; but these days a big share of that work is being automated; a big share of it is being automated through text. A big share of it is being automated through AgenTeq AI. And we are accomplishing more while using fewer resources; so those are truly the areas drawing our focus. The progress we are witnessing makes us quite enthusiastic. That patient engagement offering from AgenTeq AI is already up and running. It has been operating for months at this point. The automation of pre-billing is scheduled to launch. We have spent months testing it at this point. So these are the areas we will truly be pushing ahead on in order to generate efficiency and in the end take costs out of the business, which we know matters greatly; so that is genuinely where we began. We put real effort into it near the close of last year; and we are beginning to watch it pay off as we entered 2026.
Sarah James
analystGreat. That's really useful. Thanks.
David Grossman
analystLee, could you perhaps give us a clearer picture of how you expect mobile growth to pace itself over the course of 2026? And in your answer, maybe also shed some light on the visibility you currently have and what the pipeline might look like, including how you're taking the momentum from that one specific payer and care gap closure and using it in marketing efforts toward some of the other payers.
Lee Bienstock
executiveOf course. David, thanks for asking. So, like we said on the previous call, our real approach is to build guidance around what exists right now — the contracts in hand today, the staff on board today, the volumes we're seeing today — and then naturally, should we be in a position to add new contracts, new expansions, or more staff, we'd revise things along the way. So that's the same method we're applying this quarter. It rests on the staff we currently have, how far along we are with staffing — there's still additional headway to make there. It accounts for the contracts in hand today. It leaves out any wins that are only anticipated, focusing instead on what's already in-house right now; so when it comes to visibility, this represents the complete visibility available to us. It's the contracts we hold with the staff we have now, within the current mix of business and the customers already on board. So that piece is essential. Our genuine expectation is that the mobile health business expands as the year moves forward. There isn't a single quarter where we cross some turning point. On the mobile health side, it's truly going to build in a linear fashion, since, as I said, it incorporates every contract we currently hold. What you're essentially seeing in mobile health is roughly 40% growth year over year from 2025 to 2026. Naturally, that figure does factor in a full year of SteadyMD revenues, which, as we noted, we acquired back in October. Taking SteadyMD out of both periods, we'd still have somewhere around 10% to 15% growth year over year. So our focus for this year will be on integrating SteadyMD, deploying them throughout the DocGo Inc. platform, so that SteadyMD's clinician base is used to supervise the visits taking place inside patients' homes alongside our mobile health clinicians there, and then naturally, allowing them to expand too. But essentially, what we foresee is linear growth in mobile health as the year unfolds. Naturally, if we were to land a new contract, that might bring a step function into the growth rate, but it all rests on what we hold today — that's the visibility element of your question.
David Grossman
analystAll right. That's great, thanks. Norm, I've got a quick question for you. You mentioned, I believe, that you're expecting another batch of money from HPD at some point, possibly before this month wraps up. Do you have any idea what the holdups are right now when it comes to actually receiving that payment, or is it simply the usual bureaucratic slowdowns tied to final disbursements? Is there any chance the $20 million is at risk? From what I recall in your press release, you stated that you anticipate being paid in full, but I figured it was worth asking.
Norman Rosenberg
executiveYes, and absolutely, David. That's a fair question. To give some context, we communicate with them quite regularly. I've got someone on their side I deal with. Roughly six individuals on our end are in contact with their opposite numbers. I talk with them every week. What's been happening is that during the transition in the administration, for starters, everyone has been somewhat swamped. On top of that, they're conducting an audit — not only concerning what's owed to us, but essentially covering everything HPD has handled with all its various vendors. They engaged one of the Big Four accounting firms, working in a consulting role, to carry out a comprehensive audit on their behalf, reviewing payments already made and items still pending — a fairly standard kind of exercise. Still, I'd describe that payment as having been held hostage, so to speak, because of this specific audit, which stretched on for several months. That audit is now finished. The results are currently being compiled into documentation. That's why I believe we'll learn within just a few days what they intend to pay us in a first round of funding. After that, naturally, if there are matters where they need more details — all of which we possess — we'd supply it and keep things moving forward. So that was the main obstacle — truly getting that audit finished, which took at minimum, I'd estimate, 2 to 3 months, perhaps longer, to complete.
David Grossman
analystUnderstood. Excellent. Many thanks.
Lee Bienstock
executiveFantastic. I really appreciate all of you being here with us today, and we can't wait to talk with you again before long. Stay well.
Operator
operatorAnd this concludes today’s call. Thank you for participating. You may all disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.